Answer
Xolair (omalizumab) is indicated as add-on therapy for severe persistent allergic asthma from 6 years of age.
Sources for this answer
- Xolair 150mg Solution for Injection in pre-filled syringeNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 22Document updated
Sources checked